Definitions

1. AML is a cancer of the blood and bone marrow that attacks the body if left untreated.
2. AML is a very common form of leukemia in adults.
3. AML is a cancer that starts in cells that would normally develop into different types of blood cells.
4. AML is a cancer in which white blood cells are over-produced in the bone marrow extremely rapidly without enough time for them to mature.
5. AML is the most commonly diagnosed form of leukemia in adults, mostly affecting those over 70 years of age.

Median Age

1. The median age of patients with AML is 70; it is rare among children.
2. The median age is approximately 40 years, which is considerably younger than the other subtypes of AML (70 years).

Baseline Diagnosis

1. Response occurred in all MDS subtypes as well as in patients with adjudicated baseline diagnosis of AML in both of these studies.

Acute Myelocytic Leukemia

1. Acute myelocytic leukemia (AML) is an acute cancer that affects white blood cells, primarily those of the granulocyte or monocyte types.

Childhood Acute Myeloid Leukemia

1. Childhood acute myeloid leukemia (AML) is a cancer of the blood and bone marrow.

Different Subtypes

1. The response to cytotoxic chemotherapy among children with the different subtypes of AML is relatively similar.

Developing Aml

1. Patients who have received previous treatment with certain drugs (alkylating agents) are also at higher risk of developing AML.

Novo Aml Samples

1. Table 1 Clinical characteristics of the de novo AML samples A total of 17 samples from 14 patients with SCN were analyzed (Table 2); 2 of the patients (nos.

Acute Myeloblastic Leukemia

1. Also called AML, acute myeloblastic leukemia, acute myelocytic leukemia, acute myeloid leukemia.

Adult Aml

1. This is a very technical review of the symptoms, causes, diagnosis and treatment of adult AML.
2. Once adult AML has been diagnosed, tests are done to find out if the cancer has spread to other parts of the body.
3. Remission rates in adult AML are inversely related to age, with an expected remission rate of more than 65% for those younger than 60 years.

Bone Marrow Makes

1. Childhood acute myeloid leukemia (AML) is a type of cancer in which the bone marrow makes a large number of abnormal blood cells.
2. In AML, the bone marrow makes many unformed cells called blasts.

Childhood Cml

1. These and other symptoms may be caused by childhood AML, childhood CML, JMML, or myelodysplastic syndromes.

Result

1. It is estimated that one in four cases of acute myelogenous leukemia (AML) is the result of cigarette smoking.

Bones

1. Acute myeloid leukemia (AML) is cancer that starts inside bone marrow, the soft tissue inside bones that helps form blood cells.

Abnormalities

1. AML with 11q23 (MLL) abnormalities.

Myelodysplasia

1. Children with SDS are predisposed to myelodysplasia and AML, often with chromosome 7 abnormalities.

Health

1. Call for an appointment with your health care provider if you develop symptoms of AML.

Unknown

1. ETO possibly encodes a transcription factor, but its role in the pathogenesis of AML is unknown.

Responses

1. Responses occurred in patients with an adjudicated baseline diagnosis of AML.

Similar

1. The treatment for most subtypes of AML is similar.
2. This risk now appears similar to, rather than higher than, the risk of AML in Fanconi anaemia and dyskeratosis congenita.

Development

1. Problems with your genes may also play a role in the development of AML.

Phases

1. The treatment of childhood AML usually has two phases.
2. The treatment of adult AML usually has 2 phases.

Congenital Neutropenia

1. MDS and AML have been reported to occur in the natural history of congenital neutropenia without cytokine therapy.

Mutations

1. A new drug was found to cancel the effects of mutations of a gene known as the main culprit in AML, an aggressive, treatment-resistant form of leukemia.
2. In contrast to the de novo AML samples, no mutations of FLT3, NRAS, CEBPA, or NPM1 were detected.
3. As expected, mutations of tyrosine kinase genes (FLT3, KIT, and JAK2) were common in de novo AML, with a cumulative frequency of 30%.

Incidence

1. Geographic differences in the incidence of cytogenetic abnormalities of acute myelogenous leukemia (AML) in Spain.

Analysis

1. Prognostic factors of patients with acute myeloid leukemia (AML) allografted in first complete remission: an analysis of the EORTC-GIMEMA AML 8A trial.
2. To BMT or to not BMT for AML. This is my analysis of whether or not to have an allogeneic BMT for AML in first remission.

Survival

1. Patients were followed for survival and disease evolution to acute myeloid leukemia (AML) through December 31th, 2005.
2. AML in FA is generally very difficult to treat and survival has been very poor as observed in the presented case.

Classification

1. APL is considered a type of AML and is classified as the M3 variant of AML in the internationally accepted French-American-British (FAB) Classification.
2. In the WHO classification, the blast threshold for the diagnosis of AML is reduced from 30% to 20% blasts in the blood or marrow.

Criteria

1. Based on these criteria, only 5 of 210 tumor samples (both de novo AML and SCN samples) had inadequate sequence coverage for NRAS (Figure 1).

Drugs

1. Acute myelogenous leukemia (AML) drugs include daunorubicin, idarubicin, cytosine arabinoside, and mitoxantrone.

Certain Types

1. Recognizing these changes helps to identify certain types of AML and is important in determining the outlook for the patient.

Phase

1. Tipifarnib has undergone Phase I testing in AML, and a Phase II trial is ongoing.

Testes

1. AML may invade nonhematopoietic tissue such as meninges, brain parenchyma, testes or ovaries, or skin (leukemia cutis).

Central Nervous System

1. AML begins in the bone marrow but can spread to other parts of the body including the lymph nodes, liver, spleen, central nervous system, and testes.

Spinal Cord

1. Anticancer drugs given by mouth or vein to treat AML cannot cross the blood-brain barrier and enter the fluid that surrounds the brain and spinal cord.
2. Chemotherapy given by mouth or vein to treat AML cannot cross the blood-brain barrier and enter the fluid that surrounds the brain and spinal cord.

Baseline

1. At baseline, 32% of patients met WHO criteria for AML.
2. Using current WHO criteria, 103 patients had AML at baseline; 35% to 48% had HI or better responses.

Time

1. The length of time since treatment ended, for AML that has recurred.
2. These patients are excluded only from the AML transformation and time to progression analyses.
3. The subtypes of AML are classified based on the stage of development myeloblasts have reached at the time of diagnosis.

Onset

1. No statistically significant relationships were found between age at onset of MDS or AML and patient gender, G-CSF dose, or duration of G-CSF therapy.
2. Furthermore, the risk of developing AML increases with the onset of BM failure.

Newly

1. Untreated adult acute myeloid leukemia (AML) is defined as newly diagnosed leukemia with no previous treatment.
2. Treatment of newly diagnosed childhood acute myeloid leukemia (AML) is combination chemotherapy.
3. Whether the AML is newly diagnosed or has recurred (come back) after being treated.

Treatment Options

1. Since treatment options for relapsed AML are so limited, another option which may be offered is palliative care.

Malignant

1. AML sufferers have a high count of malignant white blood cells and an extremely low count of red blood cells.

High Rate

1. Such treatment is now avoided due to a high rate of AML transformation.

Disease

1. With treatment, younger patients with AML tend to do better than those who develop the disease at an older age.
2. Some patients of AML with subtype M5 may experience swelling of the gums due to the spread of the disease there.
3. As a result of their disease, patients with AML are often neutropenic before beginning chemotherapy [ 3].

Overall Health

1. Treatment for adult AML depends on the type of AML, the patient's age and overall health.

Progress

1. However, some forms of MDS can progress to acute myeloid leukemia (AML), a type of cancer.
2. Myelodysplastic syndromes may progress to AML.

Untreated

1. Whether the AML is untreated or has recurred (come back) after being treated.

Different Type

1. AML affects a different type of white cells than those affected by ALL.

Categories

1. Mds
2. Leukemia
3. Adults
4. Bone Marrow
5. Humans > Health > Diseases > Patients

Related Keywords

* Abnormal * Abnormal Cells * Acute Leukemia * Acute Leukemias * Acute Lymphocytic Leukemia * Acute Myelogenous Leukemia * Acute Myeloid Leukemia * Acute Nonlymphocytic Leukemia * Acute Promyelocytic Leukemia * Adults * Age * Aml Patients * Apl * Approximately 25% * Arsenic Trioxide * Benzene * Blasts * Blood * Blood Cell * Blood Cells * Bone Marrow * Bone Marrow Transplant * Bruising * Cases * Cells * Chemotherapy * Childhood Aml * Children * Chloroma * Cml * Common * Common Form * Common Illnesses * Common Type * Cytarabine * Cytogenetics * Diagnosis * Exposure * External Radiation Therapy * Fa Patients * Gemtuzumab Ozogamicin * Immature * Induction Chemotherapy * Induction Therapy * Leukemia * Leukemia Cells * Leukemic Cells * Maturation * Mature * Mds * Median Survival * Monosomy * Months * Myeloblast * Myeloblasts * Myelodysplastic Syndrome * Myelodysplastic Syndromes * Normal * Number * Older People * Outcome * Patient * Patients * Prognosis * Propensity * Q22 * Remission * Risk * Risk Factors * Signs * Squamous Cell Carcinoma * Study * Sub-Type * Subtype * Subtypes * Symptoms * Tests * Tmd * Treatment * Treatments * Type * Types * Years

1. Books about "Aml" in Amazon.com
   

Continue: More Keywords - - - - - - - - - -